Combination therapy before surgery for liver cancer that cannot be removed at first
Part of Cancer, Digestive system clinical trials.
This study tests a combination of treatments to shrink liver cancer that cannot be removed with surgery at first. The goal is to make the tumor small enough for surgery or to disappear completely, and then either have surgery or continue the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- Your liver cancer is considered unresectable, meaning surgery is not safe or possible right now.
- You have not had any prior systemic treatment (like chemotherapy or immunotherapy) for this cancer.
- Your liver function is good enough (Child-Pugh class A or B).
- You are able to perform daily activities with minimal help (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests a combination of three treatments—radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib)—to see if they can shrink liver cancer enough to make surgery possible. It is for people whose liver cancer cannot be removed right now.
This trial tests whether a combination of three drugs given before surgery can help shrink liver cancer and improve outcomes for patients whose tumors can be removed. It is for people with intermediate-stage liver cancer that is still operable.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
Hear when a new Unresectable Hepatocellular Carcinom trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.